Management of Tachycardia in Thyrotoxicosis

Mechanisms of Fatigue and Appropriate Management

• The European Society of Cardiology recommends that beta-blockers are first-line therapy for controlling ventricular rate in thyrotoxicosis-associated tachycardia, achieving heart rate endpoints in approximately 70% of patients compared to 54% with calcium channel blockers 3
• The American College of Cardiology suggests that non-dihydropyridine calcium channel antagonists (diltiazem or verapamil) should only be used when beta-blockers are contraindicated, and the dose should be carefully titrated to avoid excessive rate reduction 1, 7, 8
• The European Heart Journal states that calcium channel blockers like diltiazem have negative inotropic properties that can reduce cardiac output, particularly problematic in thyrotoxicosis where cardiac demands are increased 2, 3
• The European Heart Journal notes that diltiazem may induce reflex sympathetic activation secondary to blood pressure reduction, which can paradoxically worsen symptoms in thyrotoxicosis 2, 4

Clinical Considerations

• The European Heart Journal recommends that if changing therapy, diltiazem should be tapered to prevent rebound tachycardia 3
• The American College of Cardiology advises that if the patient has contraindications to beta-blockers (e.g., asthma, COPD), diltiazem remains an appropriate choice but may require dose adjustment 1, 9
• The European Heart Journal states that patients with thyrotoxicosis have a 10-25% risk of developing atrial fibrillation, which requires appropriate anticoagulation assessment 5, 6
• The European Heart Journal notes that in patients with thyrotoxicosis and Wolff-Parkinson-White syndrome with pre-excited AF, calcium channel blockers are contraindicated 5, 7